Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials

Figures & data

Figure 1. The flowchart of literature screening.

Table 1. The characteristics of included studies.

Author	Year	Recruitment year	Country	study type	BRCA mutation	treatment	NOS
Zhang, L.	2022	2016–2019	China	RCT	NS	epirubicin, docetaxel, and cyclophosphamide vs. docetaxel and carboplatin	7
Yan, W.	2022	2014–2019	China	RCT	NS	docetaxel, epirubicin ± lobaplatin	7
Mayer, I. A.	2021	2016–2021	USA	RCT Phase III	NS	capecitabine vs. Platinum	8
Pohl-Rescigno, E.	2020	2014–2016	Germany	RCT	NS	epirubicin, paclitaxel, and cyclophosphamide vs. paclitaxel, doxorubicin and carboplatin	5
Zhang, J.	2020	2003–2015	China	RCT	Yes	Anthracycline taxane ± carboplatin	7
Du, F.	2020	2009–2015	China	RCT Phase II	Yes	Epirubicin, cyclophosphamide followed by taxanes (paclitaxel or docetaxel) vs. carboplatin, taxanes (paclitaxel or docetaxel)	6
Schneeweiss, A.	2019	2014–2016	Germany	RCT Phase III	NS	Epirubicin, paclitaxel, and cyclophosphamide vs. paclitaxel, doxorubicin and carboplatin	8
Wu, X.	2018	2014–2017	China	RCT Phase II	NS	Docetaxel, epirubicin ± lobaplatin	8
Su, Y. W.	2018	2004–2010	China	RCT	Yes	Anthracycline taxane ± carboplatin	6
Sella, T.	2018	2013–2017	Israel	RCT Phase II	Yes	Doxorubicin and cyclophosphamide ± paclitaxel and carboplatin	7
Loibl, S.	2018	NA	Germany	RCT Phase III	Yes	Paclitaxel, doxorubicin, cyclophosphamide ± carboplatin\veliparib	8
Gluz, O.	2018	2013–2015	Germany	RCT Phase II	NS	Paclitaxel and carboplatinum vs. paclitaxel and gemcitabine	8
Vetter, M.	2017	2004–2014	Switzerland	RCT	Yes	Anthracycline taxane ± carboplatin	8
Zhang, P.	2016	2006–2012	China	RCT Phase II	Yes	Anthracycline taxane ± carboplatin	8
Rugo, H. S.	2016	2010–2012	USA	RCT Phase II	Yes	Paclitaxel, doxorubicin, cyclophosphamide ± carboplatin\veliparib	7
Sikov, W. M.	2015	2009–2012	USA	RCT Phase II	Yes	Anthracycline ± bevacizumab\platine	8
von Minckwitz, G.	2014	2011–2012	Germany	RCT Phase II	NS	Anthracycline, bevacizumab ± platine	8
Ando, M.	2014	2010–2011	Japan	RCT Phase II	NS	Anthracycline taxane ± carboplatin	8
Alba, E.	2012	2007–2010	Spain	RCT Phase II	Yes	Anthracycline taxane ± carboplatin	7

Abbreviation: RCT: randomized control trial; NOS: the Newcastle-Ottawa Quality Assessment Scale; NS: not specific

Table 2. The characteristics of patients in the included studies.

Author	Year	Group	sample	age	Premenopausal	Postmenopausal	Histological grade I	Histological grade II	Histological grade III
Zhang, L.	2022	Non platinum-based neoadjuvant treatment	44	NG	NG	NG	NG	NG	27 (61)
		Platinum-based neoadjuvant treatment	44	NG	NG	NG	NG	NG	29 (66)
Yan, W.	2022	Non platinum-based neoadjuvant treatment	101	NG	NG	NG	18 (18)	64 (63)	19 (19)
		Platinum-based neoadjuvant treatment	99	NG	NG	NG	16 (16)	62 (63)	21 (21)
Mayer, I. A.	2021	Non platinum-based neoadjuvant treatment	160	52 (26–76)	NG	NG	15 (9)	101 (63)	35 (22)
		Platinum-based neoadjuvant treatment	148	52 (27–72)	NG	NG	21 (14)	83 (56)	77 (52)
Pohl-Rescigno, E.	2020	Non platinum-based neoadjuvant treatment	34	NG	NG	NG	NG	NG	NG
		Platinum-based neoadjuvant treatment	35	NG	NG	NG	NG	NG	NG
Zhang, J.	2020	Non platinum-based neoadjuvant treatment	155	NG	NG	NG	NG	NG	NG
		Platinum-based neoadjuvant treatment	133	NG	NG	NG	NG	NG	NG
Du, F.	2020	Non platinum-based neoadjuvant treatment	154	48.0 (9.8)	90 (58)	64 (42)	54 (35)	83 (54)	17 (11)
		Platinum-based neoadjuvant treatment	154	48.8 (9.9)	94 (61)	60 (39)	62 (40)	83 (54)	9 (6)
Schneeweiss, A.	2019	Non platinum-based neoadjuvant treatment	470	48.0 (23.0e76.0)	288 (61)	182 (39)	155 (33)	202 (43)	35 (7)
		Platinum-based neoadjuvant treatment	475	48.0 (21.0e76.0)	290 (61)	185 (39)	172 (36)	196 (41)	31 (7)
Wu, X.	2018	Non platinum-based neoadjuvant treatment	63	NG	NG	NG	6 (10)	43 (68)	14 (22)
		Platinum-based neoadjuvant treatment	62	NG	NG	NG	5 (8)	36 (58)	21 (34)
Su, Y. W.	2018	Platinum-based neoadjuvant treatment	25	51.1 (31.1–70.2)	NG	NG	5 (20)	NG	NG
		Non platinum-based neoadjuvant treatment	104	53.4 (21.6–79.9)	NG	NG	23 (22)	NG	NG
Sella, T.	2018	Platinum-based neoadjuvant treatment	76	43.3 (10.4)	NG	NG	0 (0)	47 (62)	29 (38)
		Non platinum-based neoadjuvant treatment	43	42.3 (9.5)	NG	NG	2 (5)	22 (51)	19 (44)
Loibl, S.	2018	Platinum-based neoadjuvant treatment	316	51 (41–59)	NG	NG	NG	NG	NG
		Platinum-based neoadjuvant treatment	160	49 (40–57)	NG	NG	NG	NG	NG
		Non platinum-based neoadjuvant treatment	158	50 (42–59)	NG	NG	NG	NG	NG
Gluz, O.	2018	Non platinum-based neoadjuvant treatment	178	NG	NG	NG	NG	NG	NG
		Platinum-based neoadjuvant treatment	146	NG	NG	NG	NG	NG	NG
Vetter, M.	2017	Non platinum-based neoadjuvant treatment	54	51 (26–82)	NG	NG	22 (41)	30 (56)	2 (4)
		Platinum-based neoadjuvant treatment	29	53 (38–71)	NG	NG	12 (41)	14 (48)	3 (10)
Zhang, P.	2016	Non platinum-based neoadjuvant treatment	47	48 (24–73)	29 (62)	18 (38)	NG	16 (34)	31 (66)
		Platinum-based neoadjuvant treatment	44	46 (24–65)	30 (68)	14 (32)	NG	15 (34)	29 (66)
Rugo, H. S.	2016	Platinum-based neoadjuvant treatment	39	47.5 (24–71)	NG	NG	NG	NG	NG
		Non platinum-based neoadjuvant treatment	21	48.5 (27–70)	NG	NG	NG	NG	NG
Sikov, W. M.	2015	Non platinum-based neoadjuvant treatment	107	NG	NG	NG	NG	NG	NG
		Non platinum-based neoadjuvant treatment	105	NG	NG	NG	NG	NG	NG
		Platinum-based neoadjuvant treatment	111	NG	NG	NG	NG	NG	NG
		Platinum-based neoadjuvant treatment	110	NG	NG	NG	NG	NG	NG
von Minckwitz, G.	2014	Non platinum-based neoadjuvant treatment	157	47 (21–78)	NG	NG	NG	NG	NG
		Platinum-based neoadjuvant treatment	158	48 (21–75)	NG	NG	NG	NG	NG
Ando, M.	2014	Non platinum-based neoadjuvant treatment	88	47 (30–69)	60 (68)	28 (32)	16 (18)	29 (33)	43 (49)
		Platinum-based neoadjuvant treatment	91	47 (30–70)	54 (59)	37 (41)	13 (14)	35 (38)	43 (47)
Alba, E.	2012	Platinum-based neoadjuvant treatment	46	47 (27–70)	33 (72)	13 (28)	1 (2)	9 (20)	36 (78)
		Non platinum-based neoadjuvant treatment	47	47 (28–75)	29 (62)	19 (40)	2 (4)	13 (28)	33 (70)

Abbreviation: NG: not given

Figure 2. The comparison of pCR in PBAT and non-PBAT in treating TNBC.

Figure 3. The comparison of drug-related complications in PBAT and non-PBAT in treating TNBC.

Figure 4. The comparison of relapse-free survival and overall survival in PBAT and non-PBAT in treating TNBC.